SGLT2 inhibitors are the new mainstay of diabetes mellitus and cardiovascular diseases treatment. Despite the remarkable benefits, the molecular mechanisms mediating the effects of SGLT2 inhibitors on water and electrolyte balance are incompletely understood. The goal of this study was to determine whether SGLT2 inhibition alters blood pressure and kidney function via affecting the Renin-Angiotensin-Aldosterone System (RAAS) and sodium channels/transporters along the nephron in Dahl Salt-Sensitive (SS) rats, a model of salt-induced hypertension. Administration of dapagliflozin (Dapa) at 2 mg/kg/day via drinking water for 3 weeks blunted the development of salt-induced hypertension as evidenced by lower blood pressure and a left shift of the pressure natriuresis curve. Urinary flow rate, glucose excretion, and Na+ and Cl-/creatinine ratios increased in Dapa-treated compared to vehicle-treated rats. To define the contribution of RAAS, we measured various hormones. Despite apparent effects on Na+ and Cl-/creatinine ratios, Dapa treatment did not affect RAAS metabolites. Subsequently, we assessed the effects of Dapa on renal Na+ channels and transporters using RT-PCR, Western blotting, and patch-clamp. Neither mRNA nor protein expression levels of tested renal transporters (SGLT2, NHE3, NKCC2, NCC, and α-, β-, γ- ENaC subunits) changed significantly between groups. Furthermore, electrophysiological studies did not reveal any difference in Dapa treatment on the conductance and activity of ENaC. Our data suggest that SGLT2 inhibition in a non-diabetic model of salt-sensitive hypertension blunts the development of salt-induced hypertension by causing glucosuria and natriuresis without changes in RAAS and expression or activity of studied Na+ channels and transporters.